Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 138974, 7 pages
http://dx.doi.org/10.1155/2015/138974
Research Article

Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Activity in Human Glioma Samples Predicts Tumor Presence and Clinical Prognosis

1Department of Neurosurgery, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou 515041, China
2Department of Pathology, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou 515041, China
3Department of Radiology, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou 515041, China
4Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, China
5Institute of Oncologic Pathology, Shantou University Medical College, Shantou 515041, China

Received 27 July 2015; Revised 23 October 2015; Accepted 4 November 2015

Academic Editor: Robert Pichler

Copyright © 2015 Ming-Fa Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Curran and G. I. Murray, “Matrix metalloproteinases in tumour invasion and metastasis,” Journal of Pathology, vol. 189, no. 3, pp. 300–308, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Lochter, M. D. Sternlicht, Z. Werb, and M. J. Bissell, “The significance of matrix metalloproteinases during early stages of tumor progression,” Annals of the New York Academy of Sciences, vol. 857, pp. 180–193, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Hlobilkova, J. Ehrmann, P. Knizetova, V. Krejci, O. Kalita, and Z. Kolar, “Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression,” Neoplasma, vol. 56, no. 4, pp. 284–290, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Radenkovic, G. Konjevic, V. Jurisic, K. Karadzic, M. Nikitovic, and K. Gopcevic, “Values of MMP-2 and MMP-9 in tumor tissue of basal-like breast cancer patients,” Cell Biochemistry and Biophysics, vol. 68, no. 1, pp. 143–152, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-S. Yang, C.-W. Lin, Y.-S. Hsieh et al., “Selaginella tamariscina (Beauv.) possesses antimetastatic effects on human osteosarcoma cells by decreasing MMP-2 and MMP-9 secretions via p38 and Akt signaling pathways,” Food and Chemical Toxicology, vol. 59, pp. 801–807, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Kjeldsen, A. H. Johnsen, H. Sengelov, and N. Borregaard, “Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase,” The Journal of Biological Chemistry, vol. 268, no. 14, pp. 10425–10432, 1993. View at Google Scholar · View at Scopus
  8. L. Yan, N. Borregaard, L. Kjeldsen, and M. A. Moses, “The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL,” The Journal of Biological Chemistry, vol. 276, no. 40, pp. 37258–37265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Barresi, L. Reggiani-Bonetti, C. Di Gregorio, E. Vitarelli, M. P. De Leon, and G. Barresi, “Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma,” Pathology—Research and Practice, vol. 207, no. 8, pp. 479–486, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Di Carlo, “Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors,” Oncology Letters, vol. 5, no. 5, pp. 1677–1681, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Nuntagowat, K. Leelawat, and R. Tohtong, “NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation,” Clinical and Experimental Metastasis, vol. 27, no. 5, pp. 295–305, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Provatopoulou, A. Gounaris, E. Kalogera et al., “Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease,” BMC Cancer, vol. 9, article 390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Barresi, G. Tuccari, and G. Barresi, “NGAL immunohistochemical expression in brain primary and metastatic tumors,” Clinical Neuropathology, vol. 29, no. 5, pp. 317–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. E. R. Smith, D. Zurakowski, A. Saad, R. M. Scott, and M. A. Moses, “Urinary biomarkers predict brain tumor presence and response to therapy,” Clinical Cancer Research, vol. 14, no. 8, pp. 2378–2386, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Wang, T. Wang, S. Liu, D. Yoshida, and A. Teramoto, “The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades,” Brain Tumor Pathology, vol. 20, no. 2, pp. 65–72, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Moses, D. Wiederschain, K. R. Loughlin, D. Zurakowski, C. C. Lamb, and M. R. Freeman, “Increased incidence of matrix metalloproteinases in urine of cancer patients,” Cancer Research, vol. 58, no. 7, pp. 1395–1399, 1998. View at Google Scholar · View at Scopus
  17. G. D. Shah, S. Kesari, R. Xu et al., “Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas,” Neuro-Oncology, vol. 8, no. 1, pp. 38–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Galanis, J. C. Buckner, M. J. Maurer et al., “Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods,” Neuro-Oncology, vol. 8, no. 2, pp. 156–165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Zhang, L. Xu, D. Xiao et al., “Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion,” Journal of Clinical Pathology, vol. 60, no. 5, pp. 555–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. J. Xie, L. Y. Xu, H. H. Zhang et al., “Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells,” Biochemical and Biophysical Research Communications, vol. 337, no. 1, pp. 355–362, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. Z.-F. Sun, L. Wang, F. Gu, L. Fu, W.-L. Li, and Y.-J. Ma, “Expression of Notch1, MMP-2 and MMP-9 and their significance in glioma patients,” Zhonghua Zhong Liu Za Zhi, vol. 34, no. 1, pp. 26–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Sarkar and V. W. Yong, “Inflammatory cytokine modulation of matrix metalloproteinase expression and invasiveness of glioma cells in a 3-dimensional collagen matrix,” Journal of Neuro-Oncology, vol. 91, no. 2, pp. 157–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Liu, J. Wu, Z. Ying et al., “Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion,” Cancer Research, vol. 70, no. 9, pp. 3750–3759, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Yan, W. Zhang, L. Sun et al., “Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme,” Brain Research, vol. 1411, pp. 108–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Sun, Q. Wang, H. Zhou et al., “Antisense MMP-9 RNA inhibits malignant glioma cell growth in vitro and in vivo,” Neuroscience Bulletin, vol. 29, no. 1, pp. 83–93, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M.-F. Liu, T. Jin, J.-H. Shen et al., “NGAL and NGALR are frequently overexpressed in human gliomas and are associated with clinical prognosis,” Journal of Neuro-Oncology, vol. 104, no. 1, pp. 119–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Hadler-Olsen, J.-O. Winberg, and L. Uhlin-Hansen, “Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets,” Tumor Biology, vol. 34, no. 4, pp. 2041–2051, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. F. J. G. M. Kubben, C. F. M. Sier, L. J. A. C. Hawinkels et al., “Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer,” European Journal of Cancer, vol. 43, no. 12, pp. 1869–1876, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. X.-F. Zhang, Y. Zhang, X.-H. Zhang et al., “Clinical significance of neutrophil gelatinase-associated lipocalin (NGAL) expression in primary rectal cancer,” BMC Cancer, vol. 9, article 134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. C.-W. Lin, S.-W. Tseng, S.-F. Yang et al., “Role of lipocalin 2 and its complex with matrix metalloproteinase-9 in oral cancer,” Oral Diseases, vol. 18, no. 8, pp. 734–740, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. K. K. Veeravalli and J. S. Rao, “MMP-9 and uPAR regulated glioma cell migration,” Cell Adhesion and Migration, vol. 6, no. 6, pp. 509–512, 2012. View at Publisher · View at Google Scholar · View at Scopus